AU2001270377A1 - Transgenic animal model of neurodegenerative disorders - Google Patents

Transgenic animal model of neurodegenerative disorders

Info

Publication number
AU2001270377A1
AU2001270377A1 AU2001270377A AU7037701A AU2001270377A1 AU 2001270377 A1 AU2001270377 A1 AU 2001270377A1 AU 2001270377 A AU2001270377 A AU 2001270377A AU 7037701 A AU7037701 A AU 7037701A AU 2001270377 A1 AU2001270377 A1 AU 2001270377A1
Authority
AU
Australia
Prior art keywords
transgenic animal
animal model
neurodegenerative disorders
well
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270377A
Other languages
English (en)
Inventor
Paul E. Fraser
Peter H. St. George-Hyslop
David Westaway
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of AU2001270377A1 publication Critical patent/AU2001270377A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
AU2001270377A 2000-06-20 2001-06-19 Transgenic animal model of neurodegenerative disorders Abandoned AU2001270377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21253400P 2000-06-20 2000-06-20
US60/212,534 2000-06-20
PCT/CA2001/000900 WO2001097607A2 (en) 2000-06-20 2001-06-19 Transgenic animal model of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AU2001270377A1 true AU2001270377A1 (en) 2002-01-02

Family

ID=22791418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270377A Abandoned AU2001270377A1 (en) 2000-06-20 2001-06-19 Transgenic animal model of neurodegenerative disorders

Country Status (13)

Country Link
EP (3) EP2263453B1 (https=)
JP (3) JP4938956B2 (https=)
AT (2) ATE499832T1 (https=)
AU (1) AU2001270377A1 (https=)
CA (1) CA2407847C (https=)
CY (1) CY1105122T1 (https=)
DE (2) DE60118913T2 (https=)
DK (1) DK1292187T3 (https=)
ES (1) ES2262662T3 (https=)
MX (1) MXPA02011516A (https=)
PT (1) PT1292187E (https=)
SI (1) SI1292187T1 (https=)
WO (1) WO2001097607A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4662719B2 (ja) 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病の処置のための免疫学的方法および組成物
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
JP4590638B2 (ja) * 2006-03-20 2010-12-01 国立大学法人鳥取大学 家族性筋萎縮性側索硬化症（ｆａｌｓ）発症するトランスジェニックマウス
CL2007002908A1 (es) 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
CN101918564A (zh) * 2007-11-01 2010-12-15 弗·哈夫曼-拉罗切有限公司 非人类四元转基因动物
US20110214195A1 (en) * 2008-11-10 2011-09-01 The Regents Of The University Of Colorado, A Body Corporate Methods For Treating Clinical Conditions Associated With Lipoprotein Lipase Activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1995020666A2 (en) * 1994-01-27 1995-08-03 Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
JP2001517065A (ja) * 1995-06-07 2001-10-02 アセナ ニューロサイエンシーズ，インコーポレイテッド トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
US5894078A (en) 1996-02-26 1999-04-13 Advanced Bioconcept, Inc. Transgenic mouse expressing C-100 app
WO1999009150A1 (en) * 1996-08-15 1999-02-25 Bayer Corporation Method of introducing modifications into a gene
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
ATE499832T1 (de) 2011-03-15
EP1728423A2 (en) 2006-12-06
ES2262662T3 (es) 2006-12-01
EP1728423A3 (en) 2007-02-28
DK1292187T3 (da) 2006-08-21
CA2407847C (en) 2013-08-27
DE60144164D1 (de) 2011-04-14
EP1292187A2 (en) 2003-03-19
JP5070236B2 (ja) 2012-11-07
EP1292187B1 (en) 2006-04-19
ATE323408T1 (de) 2006-05-15
JP2011172600A (ja) 2011-09-08
WO2001097607A2 (en) 2001-12-27
EP2263453B1 (en) 2018-06-13
EP2263453A1 (en) 2010-12-22
JP2003535605A (ja) 2003-12-02
PT1292187E (pt) 2006-07-31
DE60118913T2 (de) 2007-01-25
EP1728423B1 (en) 2011-03-02
WO2001097607A3 (en) 2002-12-12
JP2009178162A (ja) 2009-08-13
CA2407847A1 (en) 2001-12-27
DE60118913D1 (de) 2006-05-24
JP4938956B2 (ja) 2012-05-23
MXPA02011516A (es) 2005-07-01
SI1292187T1 (sl) 2006-10-31
CY1105122T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
DK0845939T3 (da) Lysosomale proteiner produceret i mælk fra ikke-humane transgene dyr
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
AU6264996A (en) Method for identifying alzheimer's disease therapeutics usin g transgenic animal models
EP1163515A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR DISEASES WITH DISTURBED GLUCOSE TOLERENCE
ATE541923T1 (de) Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
WO2002079424A3 (en) TRANSGENIC MICE CONTAINING β3GALT2 GENE DISRUPTIONS
AU2001270377A1 (en) Transgenic animal model of neurodegenerative disorders
AU6168396A (en) Method for identifying alzheimer's disease therapeutics usin g transgenic animal models
WO2003026395A3 (en) Mo54 gene disruptions, compositions and methods related thereto
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
WO2002045498A3 (en) Transgenic mice containing channel protein target gene disruptions
WO2002081658A3 (en) Transgenic mice containing cacnb4 calcium ion channel gene disruptions
EP1414478A4 (en) INHIBITION OF NEURODEGENERATION
WO2004064768A3 (en) Animal model for alzheimer's disease
WO2004063354A3 (en) Compositions and methods for characterizing and regulating wnt pathways
FR2878852B1 (fr) Procede de production d'immunoglobulines anti-thymocytes humains
WO2002079412A3 (en) Transgenic mice containing usp3-like deubiquitinating enzyme gene disruptions
WO2005001483A3 (en) Methods for diagnisis and differential diagnosis of dementia disorders
GB9808486D0 (en) A method for evaluating the risk of developing alzheimer's disease
AU2002250457A1 (en) Methods for diagnosing alzheimer's disease
WO2002048346A3 (en) Transgenic mice containing bsmap gene disruptions
WO2002045500A3 (en) Transgenic mice containing ptp36 tyrosine phosphatase disruptions
WO2002048339A3 (en) Transgenic mice containing kir5.1 inwardly rectifying potassium channel gene disruptions
WO2002046391A3 (en) Transgenic mice containing nori gene disruptions
WO2002079425A3 (en) Transgenic mice containing clcn4 chloride ion channel gene disruptions